Why is the Mesoblast share price crashing 9% today?

What is weighing on this high-flying stock on Tuesday? Let's find out.

| More on:
Shot of a young businesswoman looking stressed out while working in an office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price has returned from its trading halt and dropped into the red.

At the time of writing, the biotech company's shares are down 9% to $2.55.

Why is the Mesoblast share price sinking today?

The catalyst for today's weakness has been news that Mesoblast has successfully completed a major capital raising.

According to the release, the allogeneic cellular medicines developer for inflammatory diseases has completed a global private placement primarily to its existing major US, UK, and Australian shareholders.

This has seen the high-flying company raise a total of A$260 million (US$160 million) at a price of A$2.50 per new share. This represents a discount of 11% to where the Mesoblast share price last traded.

Unfortunately for retail shareholders, they have been excluded from this capital raising. The company has no plans to launch a share purchase plan (SPP) on this occasion.

Why is the company raising funds?

The release notes that proceeds from the capital raising will be used to fund a number of activities.

The first is the US commercial launch of Ryoncil (remestemcel-L) for steroid-refractory acute graft-versushost disease (SR-aGvHD) in pediatric patients. It was recently approved by the US Food and Drug Administration (FDA), which put a rocket under the Mesoblast share price.

So much so, the price that Mesoblast is raising funds is a premium of 47% to where its shares were trading a month prior to Friday's trading halt.

In addition, the company notes that the funds will be used to support clinical developments. This includes the acceleration of the second Phase 3 study in inflammatory chronic low back pain (CLBP) which is actively recruiting.

Funds will also be put towards the expansion of commercial manufacturing activities in preparation for product uptake and demand, as well as working capital and general corporate purposes.

Commenting on the capital raising, Mesoblast's chief executive, Dr. Silviu Itescu, said:

We appreciate the strong support from our shareholders as we scale-up production and provide to hospitals Ryoncil, the first and only FDA-approved mesenchymal stromal cell therapeutic, to treat children with life-threatening SR-aGvHD.

Huge turnaround

This capital raising marks an incredible turnaround in the fortunes of this biotech stock. A year ago, the Mesoblast share price was in the doldrums and fetching just 28 cents. This gave it a market capitalisation of approximately $300 million.

Fast forward to today and the company has almost raised as much as its market capitalisation from a year ago at a share price almost 10x greater than it was trading at then.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Did this biotech company deliver the goods for investors? Let's see what a $1,000 investment would be worth.

Read more »